Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy

NCT04309773 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Primary Sclerosing Cholangitis
Cholestasis

Interventions

DRUG: Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy
DRUG: Placebo of Bezafibrate in addition to standard UDCA therapy

Sponsor

Assistance Publique - Hôpitaux de Paris